Your session is about to expire
← Back to Search
bb21217 for Multiple Myeloma
Study Summary
This trial is testing a new drug for people with multiple myeloma who haven't responded to other treatments.
- Multiple Myeloma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had a stroke, heart attack, or serious heart rhythm problems that require ongoing treatment or monitoring.You must have a condition that can be measured or evaluated by the doctors.You have a known disease affecting your brain or spinal cord.You have received a bone marrow transplant from another person, a gene therapy treatment for cancer, or a specific type of therapy targeting BCMA.
- Group 1: bb21217 Experimental Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has bb21217 received clearance from the FDA?
"Our team at Power believes that the safety of bb21217 sits somewhere on a scale from 1 to 3. Due to this being an early-stage Phase I trial, there is limited evidence supporting its efficacy and safety."
What is the availability of participation slots for this clinical trial?
"As conveyed on clinicaltrials.gov, the recruitment period for this trial has ended; it was originally posted in August 2017 and last updated in March 2021. However, there are 807 other trials recruiting patients at present."
How many sites are overseeing this clinical experiment?
"A total of 11 medical centres are recruiting participants for this study, including Beth Israel Deaconess Medical Center in Boston, UCSF Medical Center at Parnassus in San Francisco and Massachusetts General Hospital Cancer Centre in Nashville, as well as eight additional sites."
Share this study with friends
Copy Link
Messenger